Parkinsonism

Signs and symptoms

Parkinsonism is a clinical syndrome characterized by the four motor signs that are found in Parkinson's disease: tremor, bradykinesia (slowed movements), rigidity, and postural instability.

Parkinsonism gait problems can lead to falls and serious physical injuries. Other common signs and symptoms include:

• Tremors, as rest tremor (when resting, mostly in the hands) and/or postular tremor
• Short, shuffling gait
• Slow movements (bradykinesia)
• Loss of sound perception leading to soft speech, hypophonia
• Difficulty sleeping
• Dry skin
• Apathy
• Lack of facial expressions
• Balance problems
• Frequent falls
• Very small handwriting
• Rigid, stiff muscles
• Cogwheeling (jerky feeling in arm or leg)
• Upgaze impairment
• Plastic, dead feeling resistance known as "lead-pipe rigidity".

Conditions

Parkinsonism occurs in many conditions.

Neurological

Neurodegenerative conditions and Parkinson-plus syndromes that can cause parkinsonism include:

• Corticobasal degeneration
• Dementia with Lewy bodies
• The relationship (if any) with essential tremor is not clear.
• Frontotemporal dementia (Pick's disease)
• Gerstmann–Sträussler–Scheinker syndrome
• Huntington's disease
• Lytico-bodig disease (ALS complex of Guam)
• Multiple system atrophy (Shy–Drager syndrome)
• Neuroacanthocytosis
• Neuronal ceroid lipofuscinosis
• Olivopontocerebellar atrophy
• Pantothenate kinase-associated neurodegeneration, also known as neurodegeneration with brain iron accumulation
• Parkin mutation causing hereditary juvenile dystonia
• Parkinson's disease
• Parkinson's disease dementia
• Progressive supranuclear palsy
• Wilson's disease
• X-linked dystonia parkinsonism (Lubag syndrome)

Infectious

• Creutzfeldt–Jakob disease
• Encephalitis lethargica
• HIV infection and AIDS
• Japanese encephalitis

Toxins

Evidence exists to show a link between exposure to pesticides and herbicides and PD; a two-fold increase in risk was seen with paraquat or maneb/mancozeb exposure.

Chronic manganese (Mn) exposure has been shown to produce a parkinsonism-like illness characterized by movement abnormalities. This condition is not responsive to typical therapies used in the treatment of PD, suggesting an alternative pathway than the typical dopaminergic loss within the substantia nigra. Manganese may accumulate in the basal ganglia, leading to the abnormal movements that characterize parkinsonism. A mutation of the SLC30A10 gene, a manganese efflux transporter necessary for decreasing intracellular Mn, has been linked with the development of this parkinsonism-like disease. The Lewy bodies typical to PD are not seen in Mn-induced parkinsonism.

Agent Orange may be a cause of parkinsonism, although evidence is inconclusive and further research is needed.

Other toxins that have been associated with parkinsonism are:

• Annonaceae
• Carbon monoxide
• Carbon disulfide
• Cyanide
• Ethanol
• Hexane
• Mercury
• Methanol
• MPTP
• Rotenone
• Toluene (inhalant abuse: "huffing")

Vascular

Vascular Parkinsonism is typically caused by mini strokes. It typically affects gait, often marked with rigidity. Multiple conditions related to Vascular Parkinsonism include:

• Binswanger's disease (subcortical leukoencephalopathy)
• Vascular dementia (multi-infarct)
• Dural arteriovenous fistula / dAVF (reversible parkinsonism through fistula treatment)
• Dural arteriovenous malformation / dAVM (reversible through dAVM treatment)

Other

• Chronic traumatic encephalopathy (boxer's dementia or pugilistic encephalopathy)
• Damage to the brain stem (especially dopaminergic nuclei of the substantia nigra), basal ganglia (especially globus pallidus) and the thalamus.
• Hypothyroidism
• Orthostatic tremor
• Paraneoplastic syndrome: neurological symptoms caused by antibodies associated with cancers
• Rapid onset dystonia parkinsonism
• Autosomal recessive juvenile parkinsonism

Differential diagnosis

Secondary parkinsonism, including vascular parkinsonism and drug-induced parkinsonism.

Drug-induced parkinsonism

About 7% of people with parkinsonism developed symptoms as a result of side effects of medication, mainly neuroleptic antipsychotics, especially the phenothiazines (such as perphenazine and chlorpromazine), thioxanthenes (such as flupentixol and zuclopenthixol) and butyrophenones (such as haloperidol); and rarely, antidepressants. Yet another drug that can induce parkinsonism is the antihistaminic medication cinnarizine, usually prescribed for motion sickness; this is because besides antagonizing histamine receptors this drug antagonizes the dopamine D2 receptors. The incidence of drug-induced parkinsonism increases with age. Drug-induced parkinsonism tends to remain at its presenting level and does not worsen like Parkinson's disease.

Implicated medications include:

• Antipsychotics
• Lithium
• Metoclopramide
• MDMA (addiction and frequent use)
• Tetrabenazine
• Cinnarizine{{cite journal |first1=José F. |first2=Juan J. |url=https://movementdisorders.onlinelibrary.wiley.com/doi/10.1002/mds.870130313 |journal=Movement Disorders |publisher=International Parkinson and Movement Disorder Society/Wiley |issn=1531-8257 |editor1-first=A. Jon |editor1-last=Stoessl |editor2-first=Christine |editor2-last=Klein |editor3-first=David G. |editor3-last=Standaert |publication-place=Vancouver, British Columbia, Canada |title=Cinnarizine-induced parkinsonism: ten years later |last1=Martí-Massó |last2=Poza |doi=10.1002/mds.870130313 |pmid=9613736 |date=1 May 1998 |volume=13 |issue=3 |pages=453–456

Society and culture

In the United States, the 2021 National Defense Authorization Act (NDAA) added parkinsonism to the list of presumptive conditions associated with Agent Orange exposure, enabling affected service members to receive Veterans Affairs disability benefits.

References

References

1. (2005). "Clinical Neurology". Lange: McGraw-Hill Medical.
2. (September 2018). "Role of neuroimaging on differentiation of Parkinson's disease and its related diseases". Yonago Acta Med.
3. (September 2004). "Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance". The American Journal of Medicine.
4. (2011). "Perception of Speech by Individuals with Parkinson's Disease: A Review". Parkinson's Disease.
5. (21 January 2019). "Ganong's Review of Medical Physiology". McGraw Hill.
6. (2004). "Neurology in Clinical Practice: Principles of diagnosis and management". Taylor & Francis.
7. (January 2018). "The overlap between Essential tremor and Parkinson disease". Parkinsonism & Related Disorders.
8. (April 2016). "Frontotemporal Dementias". Continuum.
9. (July 2017). "Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium". Neurology.
10. (March 2006). "Movement disorders and Creutzfeldt-Jakob disease: a review". Parkinsonism & Related Disorders.
11. (August 2004). "Movement disorders and AIDS: a review". Parkinsonism & Related Disorders.
12. Yates, Johnie A.. (2022). "Netter's Infectious Diseases". Elsevier.
13. (May 2013). "Exposure to pesticides or solvents and risk of Parkinson disease". Neurology.
14. (August 2015). "Manganese-Induced Parkinsonism Is Not Idiopathic Parkinson's Disease: Environmental and Genetic Evidence". Toxicological Sciences.
15. (July 2015). "Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features". International Journal of Environmental Research and Public Health.
16. (November 2016). "Manganese-induced neurotoxicity: a review of its behavioral consequences and neuroprotective strategies". BMC Pharmacology & Toxicology.
17. (November 2020). "Toxin-Induced Parkinsonism". Neurol Clin.
18. (2003). "[Neurological syndromes linked with the intake of plants and fungi containing a toxic component (I). Neurotoxic syndromes caused by the ingestion of plants, seeds and fruits]". Revista de Neurología.
19. (December 2010). "Occupational neurological disorders in Korea". Journal of Korean Medical Science.
20. (January 2005). "Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease". Medical Science Monitor.
21. (September 2016). "Environmental Exposures and Parkinson's Disease". International Journal of Environmental Research and Public Health.
22. Weiss J. Chapter 151. Toluene and Xylene. In: Olson KR, ed. Poisoning & Drug Overdose. 6th ed. New York: McGraw-Hill; 2012. http://www.accessmedicine.com/content.aspx?aID=55982958. Accessed April 21, 2013.
23. (May 1994). "Parkinsonism induced by solvent abuse". Annals of Neurology.
24. "Vascular (Multi-Infarct) Parkinsonism | Baylor Medicine".
25. (2019). "Vascular Parkinsonism: A Review on Management updates". Annals of Indian Academy of Neurology.
26. (2017-03-27). "Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review". Movement Disorders Clinical Practice.
27. (1999-05-01). "Intracranial dural arteriovenous fistula (DAVF) presenting progressive dementia and parkinsonism". Journal of the Neurological Sciences.
28. (September 2015). "Dural Arteriovenous Fistula-Associated Reversible Parkinsonism with Presynaptic Dopaminergic Loss". Journal of Movement Disorders.
29. (March 2001). "Hemi-parkinsonism due to a midbrain arteriovenous malformation: dopamine transporter imaging". Movement Disorders.
30. (2022-03-29). "Pearls & Oy-sters: Arteriovenous Malformation With Sinus Thrombosis and Thalamic Hemorrhage: Unusual Cause of Parkinsonism and Dementia". Neurology.
31. (December 2009). "Regional brain stem atrophy in idiopathic Parkinson's disease detected by anatomical MRI". PLOS ONE.
32. (April 2005). "Parkinsonism following bilateral lesions of the globus pallidus: performance on a variety of motor tasks shows similarities with Parkinson's disease". Journal of Neurology, Neurosurgery, and Psychiatry.
33. Halliday, Glenda M.. (2009-12-15). "Thalamic changes in Parkinson's disease". Parkinsonism & Related Disorders.
34. (November 2001). "Fast orthostatic tremor in Parkinson's disease mimicking primary orthostatic tremor". Movement Disorders.
35. (August 2011). "Movement disorders in paraneoplastic and autoimmune disease". Current Opinion in Neurology.
36. (November 2016). "A case of rapid-onset dystonia-parkinsonism accompanied by pyramidal tract impairment". BMC Neurology.
37. (September 2000). "Autosomal recessive juvenile parkinsonism". Brain & Development.
38. (March 2023). "Treatment of Vascular Parkinsonism: A Systematic Review". Brain Sci.
39. (May 2022). "Clinical Aspects of the Differential Diagnosis of Parkinson's Disease and Parkinsonism". J Clin Neurol.
40. "Information Sheet: Drug-induced Parkinsonism". Parkinson's Disease and Society.
41. (March 2016). "Neuroleptic-induced Parkinsonism: Clinicopathological study". Movement Disorders.
42. (November 2013). "Is there a one-way street from essential tremor to Parkinson's disease? Possible biological ramifications". European Journal of Neurology.
43. Fabrizi, Monaco, Dalla Libera. (2004). "Parkinsonian syndrome following MDMA (Ecstasy) addiction". Movement Disorders.
44. (September 10, 2021). "VA adds three new Agent Orange presumptions". U. S. Department of Veteran Affairs.